Zoladex Plus Tamoxifen in Breast Cancer

Inclusion Criteria: * provision of informed consent * histologically proven HR+ operable invasive breast cancer * completion of surgery and chemotherapy(if given). * women defined as pre- or perimenopausal according to all of the following: aged 50 years or younger, at least one menstrual period during the last months. Exclusion Criteria: * clinical evidence of metastatic disease * pregnancy or breast-feeding * bilateral oophorectomy; * radiation of the ovaries * patients who, for whatever reason(eg, confusion, infirmity,alcoholism),are unlikely to comply with trial requirements * patients whose chemotherapy was started more than 8 weeks after completion of primary surgery or whose chemotherapy was completed more than 8 weeks before starting the study treatment. Chemotherapy, if given, should have been given post-operatively, ie, patients who received neoadjuvant chemotherapy are ineligible * patients who have not received chemotherapy and whose primary surgery was completed more than 8 weeks before starting the study treatment * previous hormonal therapy as adjuvant treatment for breast cancer * patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop * previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied * treatment with a non-approved or experimental drug during 1 month before entry into the study * history of hypersensitivity to active or inactive excipients of tamoxifen and Zoladex * history of bleeding diathesis (ie. Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin ) * leukopenia and/or thrombocytopenia * history of ocular fundus diseases * history of thromboembolic diseases